Key result
Dapagliflozin with or without semaglutide shows no sex difference in HbA1c reduction.
Why the study?
Sex differences in cardiometabolic risk profiles are well recognized, yet real-world treatment response data for dapagliflozin with or without semaglutide remain limited, particularly in Middle Eastern populations.
Does treatment with dapagliflozin with or without semaglutide result in sex-specific differences in short-term HbA1c reduction in a real-world Saudi Arabian cohort?
Cohort (n=391)
No
Does treatment with dapagliflozin with or without semaglutide result in sex-specific differences in short-term HbA1c reduction in a real-world Saudi Arabian cohort?
In a real-world Saudi Arabian cohort, women presented with a more severe obesity phenotype than men at baseline, but there was no statistically detectable sex difference or sex-by-treatment interaction in short-term HbA1c response to dapagliflozin with or without semaglutide.
Answers are grounded in this paper and cite their sources.
No sex-by-treatment interaction indicates comparable HbA1c responses across sexes; leaves open comparative efficacy of regimens in observational cohorts.
Sex differences in cardiometabolic risk profiles are well recognized, yet treatment response data for dapagliflozin with or without semaglutide remain limited in real-world settings, particularly in Middle Eastern populations. Using a descriptive, sex-disaggregated analysis of a real-world cohort of 391 patients (213 female, 178 male) from a tertiary care hospital in Saudi Arabia, we examined sex-related differences in baseline cardiometabolic phenotype and treatment response across BMI, HbA1c, eGFR, blood pressure, and lipid parameters. Women presented with significantly higher BMI and a more obesity-dominant phenotype, higher HDL-C, and lower diastolic blood pressure at baseline. Unadjusted sex-disaggregated comparisons of change scores showed no statistically significant sex difference for any outcome. A revised primary analysis (an ANCOVA model of follow-up HbA1c: baseline HbA1c, sex, treatment group, sex-by-treatment interaction, age, follow-up duration, an indicator for baseline HbA1c in the diabetes diagnostic range, and baseline eGFR) found no statistically detectable sex-by-treatment interaction (β = 0.060; 95% CI − 0.58 to 0.70; p = 0.86, heteroscedasticity-robust). In sex-specific contrasts from this model, DAPA+SEMA was associated with a smaller HbA1c reduction than DAPA alone in both men (β = 0.470; 95% CI 0.017 to 0.923; p = 0.042) and women (β = 0.530; 95% CI 0.091 to 0.968; p = 0.018). Sex-specific treatment effects for BMI, eGFR, and systolic BP were not formally tested. Because treatment was not randomized and DAPA+SEMA patients had substantially higher baseline HbA1c, these adjusted associations are presented as hypothesis-generating rather than causal. These findings do not support a sex-specific difference in short-term HbA1c response to dapagliflozin with or without semaglutide in this cohort. The observational design and modest sample limit generalizability.
No takes yet. Share an insight, caveat, or question.
AlTaweel et al. (2026) conducted a cohort in Cardiometabolic disease / Type 2 diabetes (n=391). Dapagliflozin plus semaglutide (DAPA+SEMA) and sex (female vs male) vs. Dapagliflozin alone (DAPA only) across sex was evaluated on Follow-up HbA1c / change in HbA1c from baseline (sex-by-treatment interaction in ANCOVA model) (beta 0.060, 95% CI -0.582 to 0.702, p=0.855). Dapagliflozin with or without semaglutide showed no significant sex-by-treatment interaction for follow-up HbA1c response in Saudi adults.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: